Resources at London Genetics

London Genetics Limited's partnerships with its founder institutions provides it with access to a network of over 3,000 investigators. This network is part of one of the largest concentrations of medical research in UK, encompassing worldwide experts across a range of  therapeutic areas and technology disciplines.

London Genetics is uniquely placed to provide pharma and biotech companies with entry to this London clinical and genetics hub. From this position we can facilitate collaboration with a range of academic groups and ensure company access to the genetic resources and pharmacogenetic expertise that they need to incorporate these approaches into drug development.

London Genetics provides company access to academic expertise

Research resources available to companies via London Genetics:

• SAMPLES for genetic investigation, DATA to interrogate
  

- DNA samples, -omic and biomarker samples collected from well-characterised patients across a range of therapeutic areas and ethnic groups
- Genetic information for data mining

 

• PATIENT COHORTS for marker discovery and inclusion in clinical trials
  

- Well-characterised patient cohorts across a range of therapeutic areas available for marker discovery and confirmation
- Well-characterised patient networks for recruitment into clinical trials
Ethnically diverse populations

Therapeutic area cohorts available via London Genetics

                      (COPD - chronic obstructive pulmonary disease      CHD - chronic heart disease)

• NETWORKS of clinical, genetic and bioinformatics experts
  

- Worldwide clinical, genetic and bioinformatic experts for participation in key opinion leader meetings and advisory meetings, to facilitate drug development

• DRUG DEVELOPMENT EXPERTISE AVAILABLE
  

- Investigator-led research and clinical development programmes Based on experience in leading clinical development programmes, design and study planning, and study implementation expertise is available
- Project management: Ensuring effective and timely delivery of projects
- Data management: management of the large complex data sets rising from genetic studies
- Consultancy and strategic planning:  advice on how, when and where to apply pharmacogenetics to clinical development, including which genetic hypotheses to test, and the type and timing of samples

• DATA AND LABORATORY SERVICES
  

- Statistical genetics: Analysis and interpretation of data, Phase III planning
- Sample analysis (DNA, RNA and proteomic):  full analysis support across a range of genetic and genomic markers, including DNA sequencing, genotyping, and expression analysis:

              -   DNA genotyping/sequencing

              -   Transcriptomics

              -   Proteomics

              -   Epigenetics

• BIOINFORMATICS:  Data interpretation and additional statistical analyses